Based on pre-asthma lesions to explore the efficacy evaluation of The NO.1 XiaoQian Prescription in the prevention and treatment of children with

Phase 1

• Conditions: wheeze; childhood asthma

• Registration Number: ITMCTR2200005648
• Lead Sponsor: Xiyuan Hospital, China Academy of Chinese Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

(1) Children aged 3-5 years;
(2) Children with past symptoms of wheezing and mAPI positive;
(3) The guardian can cooperate with the medical records, complete the scale and agree to participate in the study;
(4) Those who had used glucocorticoids, leukotriene receptor antagonists and Traditional Chinese medicine should stop taking drugs for one month before participating in this study.

Exclusion Criteria

(1)Children with negative mAPI, or have been diagnosed with childhood asthma;
(2) Patients who had taken glucocorticoid, leukotriene receptor antagonist and Traditional Chinese medicine in the last one month;
(3) The guardian has poor communication ability and compliance and cannot cooperate to complete the test;
(4) Children with congenital diseases or other diseases with serious complications;
(5) Wheezing caused by other reasons

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
umber and frequency of wheezing attacks;Incidence of children asthma;

Secondary Outcome Measures

Name	Time	Method
nable to go out for normal hours due to illness;Pulmonary function test;The emergency number;Blood Biochemistry;Hospitalization days;The daily cost;TRACK table;The number of times you hold in at night;ECG;Routine blood;FeNO;Number of emergency drug use;Number of activity restrictions;